Table 3.
Multivariable Analysis of Survival Outcomes
| Overall Survival* | GvHD-Free, Relapse-Free Survival† | Disease-Free Survival‡ | ||||||
|---|---|---|---|---|---|---|---|---|
| N | HR (95%CI) | Wald test P | HR (95%CI) | Wald test P | HR (95%CI) | Wald test P | ||
| Age | <60 | 144 | Reference | 0.009 | Reference | 0.34 | Reference | 0.009 |
| ≥60 | 66 | 2.15(1.21,3.82) | 1.26(0.79,2.02) | 2.10(1.20,3.67) | ||||
| Sex | M | 122 | Reference | 0.38 | Reference | 0.57 | Reference | 0.83 |
| F | 88 | 1.22(0.78,1.91) | 1.11(0.77,1.61) | 1.05(0.69,1.59) | ||||
| Female donor to male recipient | No | 176 | Reference | 0.35 | Reference | 0.88 | Reference | 0.88 |
| Yes | 34 | 0.74(0.40,1.38) | 0.97(0.60,1.55) | 0.96(0.56,1.64) | ||||
| Disease Risk Index | Low | 31 | Reference | 0.018 | Reference | 0.002 | Reference | <0.001 |
| Intermediate | 81 | 4.42(1.41,13.87) | 4.45(1.71,11.59) | 6.36(2.20,18.38) | ||||
| High/Very high | 78 | 4.48(1.59,12.64) | 4.85(2.03,11.57) | 7.83(2.98,20.58) | ||||
| Conditioning regimen | MAC-TBI | 71 | Reference | 0.58 | Reference | 0.14 | Reference | 0.37 |
| MAC-NonTBI | 18 | 0.52(0.15,1.78) | 0.50(0.20,1.30) | 0.44(0.14,1.38) | ||||
| RIC/NMA | 121 | 0.95(0.52,1.74) | 1.21(0.82,1.78) | 0.88(0.48,1.63) | ||||
| Donor type | Haploidentical | 172 | Reference | 0.95 | Reference | 0.50 | Reference | 0.88 |
| Mismatched unrelated | 38 | 0.98(0.54,1.77) | 0.84(0.50,1.39) | 0.95(0.52,1.76) | ||||
| ABO blood group compatibility | ABO Compatible | 139 | Reference | 0.12 | Reference | 0.21 | Reference | 0.034 |
| Minor | 32 | 0.46(0.22,0.95) | 0.57(0.33,1.00) | 0.47(0.25,0.89) | ||||
| Major | 24 | 0.56(0.26,1.21) | 0.72(0.41,1.28) | 0.47(0.24,0.93) | ||||
| Bidirectional | 15 | 0.90(0.39,2.07) | 0.87(0.42,1.83) | 0.81(0.36,1.83) | ||||
| Donor CMV serostatus | D+ | 143 | Reference | 0.39 | Reference | 0.75 | Reference | 0.65 |
| D− | 67 | 0.80(0.49,1.33) | 0.94(0.64,1.38) | 0.90(0.57,1.42) | ||||
| Recipient CMV serostatus | R+ | 177 | Reference | 0.98 | Reference | 0.74 | Reference | 0.73 |
| R− | 33 | 1.01(0.49,2.06) | 0.91(0.51,1.60) | 0.89(0.45,1.74) | ||||
| Graft source | Peripheral blood stem cells | 166 | Reference | 0.35 | Reference | 0.83 | Reference | 0.008 |
| Bone marrow | 44 | 1.32(0.73,2.37) | 1.05(0.65,1.72) | 2.12(1.22,3.70) | ||||
| Karnofsky Performance Status, % | ≥80 | 176 | Reference | 0.053 | Reference | 0.085 | Reference | 0.024 |
| <80 | 34 | 1.70(0.99,2.91) | 1.50(0.95,2.38) | 1.81(1.08,3.02) | ||||
| HCT-Comorbidity Index | 0–2 | 125 | Reference | 0.035 | Reference | 0.32 | Reference | 0.23 |
| ≥3 | 85 | 1.61(1.03,2.51) | 1.20(0.84,1.73) | 1.29(0.85,1.95) | ||||
| Tacrolimus initial dosing method | Flat | 131 | Reference | 0.30 | Reference | 0.82 | Reference | 0.046 |
| Weight-based | 79 | 1.27(0.81,2.00) | 1.05(0.72,1.53) | 1.53(1.01,2.32) | ||||
| Tacrolimus at initial steady state, ng/mL | <10 | 176 | Reference | 0.32 | Reference | 1.00 | Reference | 0.29 |
| ≥10 | 34 | 1.35(0.75,2.42) | 1.00(0.62,1.63) | 1.38(0.77,2.47) | ||||
*
Adjusted for Age, Disease Risk Index, Karnofsky Performance Status, HCT-Comorbidity Index and Conditioning Regimen
†
Adjusted for Disease Risk Index and Conditioning Regimen
‡
Adjusted for Age, Disease Risk Index, ABO blood group compatibility, Graft source, Karnofsky Performance Status and Conditioning Regimen